FDA Inspection 1006668 — Hetero USA Inc

Hetero USA Inc — FEI 3008903511

The FDA completed an inspection of Hetero USA Inc on Mar 17, 2017 in Piscataway, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 3 citations were issued during this inspection. Product area: Drugs.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Mar 17, 2017
Fiscal Year
2017
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Piscataway, NJ (United States)

Additional details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
673021 CFR 314.80(b)Failure to develop written procedures
673121 CFR 314.80(c)[NDA prod] Fail to submit report in apprvd electronic format
683121 CFR 314.80(c)(2)Late submission of quarterly safety reports

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.